Moderna (MRNA) Accumulated Expenses (2017 - 2026)

Moderna (MRNA) has 10 years of Accumulated Expenses data on file, last reported at $1.9 billion in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 91.01% year-over-year to $1.9 billion in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 91.01% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 2.87% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.9 billion, up from $1.4 billion in the prior quarter.
• Over the last five years, Accumulated Expenses for MRNA reached as high as $2.2 billion in Q3 2023 and fell as low as $987.0 million in Q2 2025.
• Historically, Accumulated Expenses has averaged $1.6 billion across 5 years, with a median of $1.5 billion in 2023.
• Across the five-year window, Accumulated Expenses surged 113.55% in 2022 and sank 38.13% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $2.1 billion in 2022, then slipped by 14.42% to $1.8 billion in 2023, then slipped by 20.63% to $1.4 billion in 2024, then retreated by 2.87% to $1.4 billion in 2025, then soared by 37.95% to $1.9 billion in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.9 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.2 billion in Q3 2025.